DUBLIN, IRELAND--(MARKET WIRE)--Jun 24, 2008 -- Trinity Biotech plc (NasdaqGS:TRIB - News), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is pleased to announce the launch of its new HIV Incidence Assay.
The HIV-1 BED Incidence Assay is a second generation assay designed to detect recent HIV seroconversion by determination of the relative proportion of HIV specific IgG to total IgG. The HIV Incidence Assay is used for surveillance purposes by health agencies on a global basis to assist, monitor, and evaluate HIV prevention programs; to help plan vaccine trials; to identify high risk populations; and to target resources used in the fight against HIV. It is a vital tool in determining the spread of the disease. The test was developed by the U.S. Centers for Disease Control and Prevention (CDC). The test will be manufactured by Trinity, which includes Trinity developed key reagent “BED peptide,” at its facility in Carlsbad, California, under a licensing agreement with CDC.
The product is currently used at the HIV Sentinel Surveillance Centres in countries that provide surveillance data to UNAIDS and WHO (primarily in sub-Saharan Africa and Asia). Other potential opportunities for the product, following relevant regulatory approval, include assessing persons for their eligibility for HIV studies.
“The HIV-1 BED Incidence Assay is an important and complementary test to our Uni-Gold Rapid HIV platform in use throughout Africa and other emerging economies of the world impacted by HIV / AIDS,” commented Brendan K. Farrell, CEO of Trinity Biotech. “We are delighted to offer this new HIV Incidence Assay and believe it will serve as an invaluable tool to global health agencies tracking the spread of the disease. I commend our colleagues at the CDC for their leadership during this collaboration and look forward to working with them to ensure that it is made available everywhere.”
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company’s website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission.
Contact:
Contact: Trinity Biotech plc Brendan Farrell CEO Investor Relations Officer (353)-1-2769800 Email Contact
Joe Diaz, Joe Dorame, Robert Blum Lytham Partners, LLC (602) 889-9700
Source: Trinity Biotech
